Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PC5A
|
|||
| Former ID |
DNC009879
|
|||
| Drug Name |
VER-156084
|
|||
| Synonyms |
VER-156084; CHEMBL555563; BDBM50296484
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Neuropathic pain [ICD-11: 8E43.0] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H23Cl2N3O2
|
|||
| Canonical SMILES |
C1CCN(CC1)C(=O)N2CC(C2)OC(C3=CC=C(C=C3)Cl)C4=C(N=CC=C4)Cl
|
|||
| InChI |
1S/C21H23Cl2N3O2/c22-16-8-6-15(7-9-16)19(18-5-4-10-24-20(18)23)28-17-13-26(14-17)21(27)25-11-2-1-3-12-25/h4-10,17,19H,1-3,11-14H2/t19-/m0/s1
|
|||
| InChIKey |
QEKKZTBXSULKCC-IBGZPJMESA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Inhibitor | [1] |
| Cannabinoid receptor 2 (CB2) | Target Info | Inhibitor | [1] | |
| Fatty acid amide hydrolase (FAAH) | Target Info | Inhibitor | [1] | |
| BioCyc | Anandamide degradation | |||
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Rap1 signaling pathway | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Anandamide degradation | ||||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| BDNF signaling pathway | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4241-4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.